PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
Healthcare
$0.92 +1.21%
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
52W Low $0.51High $1.67
Volume 5.25M
Average 1.04M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$31.54M
FY 2025 · Annual
Net Income
-$34.50M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 57.33K | 59.79K | 0 |
| Gross Profit | 0 | 0 | (57.33K) | (59.79K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 11.25M | 29.43M | 27.76M | 22.57M | 19.03M |
| Selling, General & Admin | 10.18M | 12.24M | 15.28M | 13.7M | 12.52M |
| Operating Expenses | 21.44M | 41.67M | 43.05M | 36.26M | 31.54M |
| Depreciation & Amortization | 5.36K | 86 | 57.33K | 59.79K | 21.84K |
| EBITDA | (21.43M) | (40.74M) | (40.09M) | (33.75M) | (30.3M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.44M) | (41.67M) | (43.05M) | (36.32M) | (31.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4.35K | 935.18K | 2.9M | 2.52M | 1.22M |
| Interest Expense | 0 | 1.32M | 4.21M | 4.67M | 5.34M |
| Other Income / Expenses | 4.35K | (381.34K) | (1.3M) | (2.16M) | (4.12M) |
| Income Before Tax | (21.43M) | (42.05M) | (44.35M) | (38.48M) | (35.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.52M) | (1.2M) | (1.41M) | (869.17K) | (1.17M) |
| Net Income | (16.92M) | (40.85M) | (42.94M) | (37.61M) | (34.5M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| EPS (Diluted) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| 25.6M | 28.6M | 30.95M | 36.45M | 46.38M | |
| 25.6M | 28.6M | 30.95M | 36.45M | 46.38M |
PDSB Earnings Waterfall · TTM
NASDAQ:PDSB · Revenue to Net Income
Key Ratios
EPS$-0.67
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.3
P/S Ratio0.0
Analysis
$0 of revenue converted into -$33.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.67, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 21, 2026 | |
| 8-K | Current report | Oct 21, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 21, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 20, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 |
How much revenue does PDSB generate?
PDS Biotechnology Corporation (PDSB) reported $0.00 of revenue in fiscal 2025.
Is PDSB profitable?
PDS Biotechnology Corporation (PDSB) reported -$34.50M of net income.
Continue the stock analysis
Jump to another research area for this company.